• Citer

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

par Loi, Sherene ;Sirtaine, Nicolas;Piette, Fanny;Salgado, Roberto;Viale, Giuseppe;Van Eenoo, Françoise;Rouas, Ghizlane;Francis, Prudence;Crown, John P A;Hitre, Erika;Azambuja, Evandro ;Quinaux, Emmanuel;Di Leo, Angelo ;Michiels, Stefan ;Piccart-Gebhart, Martine ;Sotiriou, Christos
Référence Journal of clinical oncology, 31, 7, page (860-867)
Publication Publié, 2013-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Previous preclinical and clinical data suggest that the immune system influences prognosis and response to chemotherapy (CT); however, clinical relevance has yet to be established in breast cancer (BC). We hypothesized that increased lymphocytic infiltration would be associated with good prognosis and benefit from immunogenic CT-in this case, anthracycline-only CT-in selected BC subtypes.